Health and Medicine
Nov. 18, 2020—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.
Nov. 17, 2020—Further research by biochemistry professors Charles Sanders and Bruce Carter into therapeutics for Charcot-Marie-Tooth disease, an inherited condition that damages peripheral nerves, will be funded by Ancora Innovation LLC, a Deerfield Management company that supports Vanderbilt’s innovative life science research.
Nov. 17, 2020—Vanderbilt biochemists figure out how the little-understood Envelope protein helps SARS-CoV-2 function and how to disrupt the endogenously creative virus.
Nov. 16, 2020—Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19.
Nov. 12, 2020—Vanderbilt contributes molecular imaging data of kidney to the Human BioMolecular Atlas Program, a consortium of 18 diverse collaborative research teams across the United States and Europe.
Nov. 12, 2020—Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer.
Nov. 12, 2020—A new study from Vanderbilt epidemiologists suggests that it’s time to reconsider clinical practice guidelines for the treatment of early-stage breast cancer in older women.
Nov. 11, 2020—Vanderbilt University Medical Center health policy experts share what’s next for drug policy, insurance coverage, health care access and pandemic response in a free virtual discussion on Monday, Nov. 16.
Nov. 10, 2020—A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.
Nov. 9, 2020—Findings from a national study published Nov. 9 in the Journal of the American Medical Association (JAMA) “do not support” the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19, the report concludes.
Nov. 9, 2020—Yi Ren, assistant professor of biochemistry, has contributed to research on the function and impact of the SARS-CoV-2 protein on immune signaling protein in host cells. This understanding may lead to the development of immune-enhancing therapeutics.
Nov. 6, 2020—Assistant Professor of Biochemistry Yi Ren and her team have made several discoveries to illuminate the mechanisms of key host-pathogen interactions involving viruses, with implications for gaining a better understanding of SARS-CoV-2, the virus that causes COVID-19.